MEDIA

Press Releases

Select Year

FDA Accepts Revance’s BLA Resubmission for DaxibotulinumtoxinA

FDA Accepts Resubmitted BLA for Cosmetic Therapy

FDA Accepts Revance Resubmission for Frown Line Therapy

Will A Biotech Rival Finally Shake Up Abbvie’s $2B Botox Cosmetic Franchise? Revance Will Find Out Soon